BEIJING (Reuters) – China’s National Medical Products Administration (NMPA) said on Wednesday it has approved the first CAR-T cell therapy in the country.
The drug Yescarta is approved to treat adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, NMPA said in a statement on its website.
A joint venture of Shanghai Fosun Pharmaceutical Group has obtained the rights from Kite Pharma, a subsidiary of U.S. drugmaker Gilead, to sell the therapy in China, Hong Kong and Macau, and plans production in mainland China, Fosun Pharma filings showed.
(Reporting by Roxanne Liu and Ryan Woo; Editing by Jacqueline Wong)
